Market closed
Conduit Pharmaceuticals Inc./$CDT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Ticker
$CDT
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
6
Website
CDT Metrics
BasicAdvanced
$5.8M
-
-$20.53
2.27
-
Price and volume
Market cap
$5.8M
Beta
2.27
52-week high
$1.40
52-week low
$0.51
Average daily volume
4.9M
Financial strength
Current ratio
0.253
Quick ratio
0.052
Long term debt to equity
-1.575
Total debt to equity
-109.775
Interest coverage (TTM)
-10.24%
Management effectiveness
Return on assets (TTM)
-168.82%
Return on equity (TTM)
491.09%
Valuation
Price to book
-0.18
Price to tangible book (TTM)
-0.18
Price to free cash flow (TTM)
-0.077
Growth
Earnings per share change (TTM)
130.17%
CDT News
AllArticlesVideos
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
GlobeNewsWire·5 days ago
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
GlobeNewsWire·2 weeks ago
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Conduit Pharmaceuticals Inc. stock?
Conduit Pharmaceuticals Inc. (CDT) has a market cap of $5.8M as of April 16, 2025.
What is the P/E ratio for Conduit Pharmaceuticals Inc. stock?
The price to earnings (P/E) ratio for Conduit Pharmaceuticals Inc. (CDT) stock is 0 as of April 16, 2025.
Does Conduit Pharmaceuticals Inc. stock pay dividends?
No, Conduit Pharmaceuticals Inc. (CDT) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Conduit Pharmaceuticals Inc. dividend payment date?
Conduit Pharmaceuticals Inc. (CDT) stock does not pay dividends to its shareholders.
What is the beta indicator for Conduit Pharmaceuticals Inc.?
Conduit Pharmaceuticals Inc. (CDT) has a beta rating of 2.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.